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We examined the effect of inoculum dose on SHIV transmission and infection. We found that repeated low-dose intravaginal exposure with
either R5-SHIVSF162P3 or X4-SHIVSF33A results in infections that are blunted and rapidly controlled. Interestingly, although the transmission rate
after all repeated exposures is comparable for the two viruses, the probability of low-dose vaginal transmission is greater for the X4 than R5 virus.
Furthermore, X4-SHIVSF33A replication predominates in low-dose dually-exposed macaques, suggesting that it is better at establishing a systemic
infection following transmission. However, X4-SHIVSF33A advantage in transmission and infection is not observed in macaques inoculated
intravenously with low-dose mixed inoculum. The finding that although matched in tissue culture infectious dose, the X4 inoculum is more
complex leads us to hypothesize that the greater genetic heterogeneity of the X4 virus population may have rendered it less susceptible to the
severe bottleneck effects imposed by IVAG inoculation with small doses, allowing for greater probability of transmission and establishment of a
generalized infection. These data have implications for HIV-1 transmission and infection in humans.
© 2006 Elsevier Inc. All rights reserved.Keywords: SHIV; Vaginal transmission; Dose effectIntroduction
It is generally believed that a successful HIV-1 infection, on
a per exposure basis, is a low-probability event (Gray et al.,
2001), but increases in persons who have a history of multiple
exposures or other sexually transmitted diseases (DeGruttola et
al., 1989; Galvin and Cohen, 2004; Jewell and Shiboski, 1990).
Furthermore, a correlation between plasma viral load and
transmission probability has been reported (Garcia et al., 1999;
Gray et al., 2001; Quinn et al., 2000), with recent studies
showing that the risk of HIV-1 transmission is increased in the
setting of primary infection when viral burden is highest
(Pilcher et al., 2004; Wawer et al., 2005). The relationship
between dose and HIV-1 transmission is noteworthy, suggesting⁎ Corresponding author. Fax: +1 212 448 5159.
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doi:10.1016/j.virol.2006.12.024that intervention or vaccine strategies that lower the viral load
might have a significant impact in reducing transmission and/or
ameliorating disease course (Gray et al., 2003; Mellors et al.,
1996).
Because of the similarities existing between humans and
non-human primates with regard to the populations of target
cells, the physiology and immunology of the female genital tract
(Hendrickx and Cukierski, 1987; Miller and Lu, 2003), simian
immunodeficiency virus (SIV) or chimeric simian/human
immunodeficiency virus (SHIV) infection of rhesus macaques
has been commonly used to study HIV-1 transmission in a
controlled manner (Miller, 1994) and to screen intervention
strategies aimed at reducing HIV-1 transmission or infection
(Shattock and Moore, 2003). To achieve high infection rates and
limit group sizes for these animal studies, virus doses ranging
from 103 to 105 50% tissue culture infectious doses (TCID50)
are routinely used. These doses are far greater than that required
to infect humans and may underestimate beneficial effects of
208 L. Tsai et al. / Virology 362 (2007) 207–216strategies that could protect against infections in real life
settings. Animal models that more closely mimic HIV-1
transmission by repeated low-dose exposure, therefore, are
needed for studies of the biology of HIV-1 transmission and for
identification of effective vaccine and microbicide candidates.
In this study, rhesus macaques (RM) were exposed
intravaginally (IVAG) to single high or multiple low dose of
the pathogenic X4 SHIVSF33A, R5 SHIVSF162P3, and mixtures
containing varying proportions of the two viruses. Intravaginal
(IVAG) exposures were chosen because male to female
transmission causes the majority of HIV-1 infections world-
wide (UNAIDS/WHO, 2005). The probability of transmission
and the biology of infection in macaques infected as a result of
exposures to small but repeated inocula doses were compared
to that seen in macaques infected with high dose inocula to
determine if there is an inoculum effect. We report that
infection outcome differs in macaques infected with high- and
low-dose SHIV inocula. Both R5 SHIVSF162P3 and X4
SHIVSF33A can be transmitted efficiently, even at low doses,
but the probability of transmission and infection with low-dose
X4 SHIVSF33A is greater than with R5 SHIVSF162P3. Because
the heterogeneous genetic nature of HIV-1, which is drastically
reduced in the presence of transmission bottleneck, is thought
to play a central role in the establishment of viral infection and
persistence by allowing for rapid evolution and adaptation
(Coffin, 1995), we hypothesize that the greater efficiency of
low-dose vaginal transmission of the X4 over the R5 SHIV
virus is linked to the greater genetic complexity of the X4 viral
quasispecies.Fig. 1. Viremia (viral RNA copies/ml plasma) and CD4+ T cell counts (per μl blood)
(B) X4 SHIVSF33A.
+Indicates progression to simian AIDS (SAIDS).Results
Pathogenic infection in macaques exposed IVAG to single high
dose of R5 SHIVSF162P3 or X4 SHIVSF33A
Four RM each were inoculated with a single high inoculum
dose of R5 SHIVSF162P3 or X4 SHIVSF33A. All four macaques
inoculated with 5000 TCID50 of R5 SHIVSF162P3 were infected,
with varying peak (105–108 RNA copies/ml plasma) and
chronic (102–104) viremia (Fig. 1A). Progressive loss of
peripheral CD4+ T cells was seen in R183 and BC81, the two
infected macaques with sustained viremia. R183 was a rapid
progressor and was euthanized at 5.5 wpi. At the time of death,
R183 had high viral loads, low CD4 T cell count, a body weight
loss greater than 20%, chronic diarrhea nonresponsive to
therapy, moderate enterocolitis, severe thymic dysinvolution
and generalized lymphoid dysplasia. No definitive evidence of
an opportunistic infection was found but the animal did have a
multifocal pneumonia consistent with a viral infection. BC81
also progressed to disease at 81 wpi, but the other two infected
macaques controlled their infection at 10–15 wpi and have been
clinically healthy for over 2 years. Thus, consistent with
previous findings (Harouse et al., 2001), IVAG infection with
R5 SHIVSF162P3 in RM mimics HIV infection of humans, with
natural variation in the level of viremia and disease course
(Mellors et al., 1995).
Three of four macaques inoculated once with 3000 TCID50
of X4 SHIVSF33Awere also systemically infected, reaching peak
viremia of 107–108 RNA copies/ml plasma (Fig. 1B). Varyingin macaques infected IVAG with a single high dose of (A) R5 SHIVSF162P3 and
Table 1
Cumulative transmission, replication and pathogenesis data from macaques exposed IVAG to high dose (>3000 TCID50) of different R5 SHIVSF162P3 and X4
SHIVSF33A virus stocks
Virus Infected/exposed Probability of transmission Peak viremia Viral setpoint SAIDS/infected Time to SAIDS
R5-SHIVSF162P3 11/13 0.85 10
5–108 102–106 6/11 5.5–104 weeks
X4-SHIVSF33A 9/16 0.56 10
6–109 102–107 7/9 30–156 weeks
Results shown are tabulated from contemporaneous study of eight macaques and historic studies in which 9 and 12 macaques were exposed IVAG to R5 and X4 SHIV
respectively. The historic studies were conducted using different virus stocks and with challenge doses that are equal or greater for the X4 SHIV.
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well, with T034, the macaque with the highest viral burden
progressing to SAIDS at 38 wpi. A rapid and precipitous drop in
peripheral CD4+ T cell numbers, characteristic of pathogenic
X4 SHIV infection, accompanied the rise in viremia. Table 1
provides a summary, based on results from contemporaneous
inoculations of eight macaques as well as historic studies using
different virus stocks, infection characteristics with high dose
IVAG challenge of the two viruses, showing a trend towards
greater probability of high dose R5 SHIVSF162P3 (0.85 per
exposure) than X4 SHIVSF33A (0.56 per exposure) transmissionFig. 2. Viremia (viral RNA copies/ml plasma) and CD4+ T cell counts (per μl blood)
SHIVSF33A. Numbers in brackets indicate the number of exposures required to esta
variability in viremia of low dose R5 SHIVSF162P3 and X4 SHIVSF33A infected maca(p=0.13), but one-log higher peak and chronic virus loads in
animals infected with the latter.
Transient and attenuated infections in macaques repeatedly
exposed IVAG to low dose R5 or X4 SHIV
Six RM each were exposed to weekly inoculum dose
containing 50 TCID50 of the same viruses used for high dose
challenge. Avariable number of exposures, ranging from 1 to 13,
were required to establish systemic infection in all five R5
SHIVSF162P3 exposed macaques (one macaque died of unrelatedin macaques exposed weekly to 50 TCID50 of (A) R5 SHIVSF162P3 and (B) X4
blish systemic infection in each of the macaque. Panels C and D highlight the
ques respectively.
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Fig. 3. Envelope variants in high and low dose (A) R5 SHIVSF162P3 and (B) X4
SHIVSF33A infected macaques. Variants were analyzed in plasma collected at 2–
3 weeks post-infection and HMA profiles are shown.
210 L. Tsai et al. / Virology 362 (2007) 207–216causes 3 weeks into the study), with a probability of transmission
of 0.161 (per exposure) (Fig. 2A). The resulting systemic
infection by multiple low-dose exposures differs from that of
classic systemic R5 SHIVSF162P3 infection which follows high
dose inoculations with the same virus stock (Fig. 1A). Peak
viremia of 103–105 RNA copies/ml was 2–3 logs lower and
none of the infected animals in the low-dose group sustained
viremia above the detection limit of 125 copies/ml. Furthermore,
there was no evidence of peripheral CD4+ T cell loss. Of note,
viral “blips” preceded the onset of a systemic infection in 2 of 5
infected macaques (V558 and V785) (Fig. 2C). Additionally, in
monkey N172 for example, multiple peaks in viremia that
progressively decreased in magnitude were seen. Since this
animal received a total of 6 inoculations, the last one at 5 weeks
post-inoculation, it is unlikely that these viral peaks occurring at
weeks 12 and 16 post-inoculation are due to re-infection.
Collectively, the data show that the infection is attenuated and
the pattern of virus replication more variable in the low-dose
than high-dose R5 SHIVSF162P3 IVAG infected animals.
Interestingly, only 2–3 exposures were required to establish
systemic infection in all six macaques that were inoculated
weekly with 50 TCID50 of X4 SHIVSF33A (Fig. 2B), with a
probability of transmission of 0.353. Thus, although a 100%
transmission rate is seen with 50 TCID50 inoculum dose of the
R5 (5/5 animals) and X4 (6/6 animals) SHIV after all repeated
exposures, the probability of low-dose vaginal transmission is
significantly higher for the X4 than R5 virus (p=0.048). The
resulting infection in low-dose X4 SHIVSF33A infected maca-
ques also differs from the classic systemic infection that follows
a single high-dose exposure (Fig. 1B). With the exception of
macaque BT65 where peak viremia of 2×107 RNA copies/ml
was reached, values in the low-dose infected animals were
substantially lower, ranging from 4×102 to 4×104 RNA copies/
ml. Consequently, only BT65 showed peripheral CD4+ T cell
loss, but the extent of this loss (∼50%) was less than that seen in
the high dose infected animals (>95%). Viremia was rapidly
controlled in all but BR52, where low level virus replication
persisted. However, a second rise in viremia at week 8 and 9
post-inoculation respectively was seen in macaques BT77 and
AG67 (Fig. 2D). Since all the animals received a total of 8
inoculations, the last one at week 7, the increase in virus
replication could be the result of re-infection. Interestingly, the
rise in peak viremia to values of 105–106 RNA copies/ml plasma
was accompanied by peripheral CD4+ T cell loss in AG67 but
not BT77. Taken together, the data show that infection with low-
dose inoculum of X4 SHIVSF33A is also attenuated. However,
although a dilution effect was seen for both viruses, the finding
that the difference in the probability of R5 high- (n=4) vs
repeated R5 low-dose (n=5) IVAG transmission (p=0.024) is of
greater significance than that seen for X4 high- (n=4) vs
repeated X4 low-dose (p=0.045) suggests that R5 SHIVSF162P3
transmission is more susceptible to the inoculum effect.
Furthermore, since strong correlation between peak viral load
and the extent of CD4+ T cell depletion in acute infection has
been reported for X4 SHIV89.6P (Davenport et al., 2006), the
lack of CD4+ T cell depletion in BT77 raises the possibility of
transmission of less pathogenic viral variants.Transmission of variants in macaques repeatedly exposed
IVAG to low dose R5 or X4 SHIV
To determine whether the attenuated replication phenotype
seen in both X4 and R5 SHIV low dose infected macaques is
due to the transmission of virus variants with lower pathogenic
potential, heteroduplex mobility assay (HMA) was employed to
examine the composition of the transmitted virus. Results
showed transmission of the major variant in all four of the R5
high-dose infected macaques as well as four of the five
macaques infected by low-dose exposures (Fig. 3A). The
exception was V785, in which HMA pattern revealed a slight
difference in band migration.
Analysis of the X4 infected macaques also indicated
transmission of the most common variant in the inoculum in
all three high dose infected macaques. Although viral loads in
two of the low-dose infected macaques were too low for
successful amplification, analysis of transmitted viruses in the
other four animals (Fig. 3B) showed transmission of minor
variants in BT77 and BR52. Interestingly, these are the two
macaques that had unusual viral replication patterns (Figs. 2B
and D). High viremia peak but little CD4 depletion was seen in
macaque BT77 while virus replication in BR52 persisted, albeit
at low levels. Thus, there was a tendency for transmission of
minor variants with apparent differential phenotypic and
replicative properties following low-dose X4 SHIVSF33A
IVAG infection. Nevertheless, the finding that similar to high-
211L. Tsai et al. / Virology 362 (2007) 207–216dose challenge macaques, infection in most multiple low-dose
challenge monkeys is initiated with the most common variant
indicates that the attenuated infections seen in these animals
cannot be attributed solely to the transmission of variants that are
less fit.
Selective advantage of X4 SHIVSF33A transmission and
replication in macaques repeatedly exposed IVAG to low dose
mixed inocula
We previously reported that while both X4 SHIVSF33A and
R5 SHIVSF162P3 were simultaneously transmitted as high-dose
mixed inocula, replication of R5 SHIV predominated following
primary infection (Harouse et al., 2003). The unexpected finding
of greater probability of transmission with low-dose X4
SHIVSF33A than R5 SHIVSF162P3 prompted us to examine
whether the selective advantage of the X4 virus is manifested in
the setting of repeated low-dose exposures with mixed
inoculum. Six female RM therefore were exposed to weekly
inocula containing 25 TCID50 of each virus. Results showed that
a varying number of exposures, ranging from 1 to 12 were
required to achieve systemic infection in five of the six animals
(probability of transmission of 0.128), with macaque AP06
remaining unsuccessfully challenged after 13 exposures (Fig.
4A). Peak viremia of 104 to 106 RNA copies/ml was reached,
with one animal (R024) sustaining high viral load and
progression to SAIDS at 38 wpi. Precipitous drop in peripheral
CD4+ T cells, indicative of the presence of X4 SHIVSF33A, was
seen in macaque R024. CD4+ T cell loss, although lessFig. 4. Viremia, CD4+ Tcell counts and genotype of replicating virus in macaques exp
of 25 TCID50 each of R5 SHIVSF162P3 and X4 SHIVSF33A. Genotype of replicatin
Percentage of circulating X4 virus is shown. + Indicates progression to simian AIDSsustained, was also present in three other infected animals
(BV09, CC70, CL49) but was not noticeable in macaque CD03.
Genotyping results showed the presence of both X4 and R5
SHIVs in macaque R024, but only X4 SHIVSF33A in BV09,
CC70 and CL49, and R5 SHIV162P3 in CD03. In the dually-
infected macaque R024, the X4 virus dominated. The finding of
either X4 or R5 circulating virus in four of the five low-dose
dually-exposed macaques is consistent with the stochastic
nature of IVAG infection (Greenier et al., 2001), which is
accentuated with the use of small inoculum dose (Wick and
Self, 2000). However, the trend for selective transmission of X4
SHIVSF33A in low-dose dually-exposed macaques and its
dominance in the dually-infected macaque contrast with
findings we previously reported using high dose challenges
(Harouse et al., 2003).
The selective advantage of low-dose IVAG X4, compared to R5
SHIV transmission, is not linked to differences in infectious
inoculum dose of the two viruses and is abrogated with
intravenous inoculation
The greater probability of transmission and growth of X4
SHIVSF33A under low-dose IVAG co-infection setting could be
due to an inherent replicative property of the X4 virus. Indeed,
in vivo replication had been suggested to predict efficiency of
vaginal transmission of SIV and SHIV in RM (Miller et al.,
1998). Alternatively, the inoculum dose, which is based on
TCID50, could be underestimated for the R5 virus as a result of
in vitro titration conditions. Although we deem this latterosed weekly intravaginally (A) or intravenously (B) to mixed incoula consisting
g virus in IVAG and IV infected macaques was determined by real-time PCR.
(SAIDS).
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seen after all repeated vaginal exposures to 50 TCID50 of the
two viruses (Figs. 1 and 2), we inoculated four RM intra-
venously (IV) with the same dose of mixed inoculum (25
TCID50 of X4 and R5 SHIVs) as the one used for IVAG co-
challenge and monitor the genotype of the replicating virus. As
there is no bottleneck, all variants present in the inoculum
should be transmitted with IV inoculation. As expected, all four
animals inoculated IV were infected, reaching peak titers of
106–107 RNA copies/ml with one (J666) progressing to SAIDS
at w24 (Fig. 4B). Precipitous peripheral CD4+ T cell loss,
indicative of the presence of X4 SHIVSF33A, was detected in all
four infected macaques. Genotyping readily detected both
viruses in three of the four IV dually-exposed macaques. The
exception being CA46 where <2% of circulating virus was of
the R5 genotype. Importantly, in those macaques where both
viruses could be readily detected, the R5 virus dominated. The
finding of similar transmission rates of the X4 and R5 virus with
25 TCID50 each in IV co-challenge further illustrates that the R5
SHIV162P3 inoculum dose is not underestimated, and predomi-
nance of the R5 SHIV in three of four low-dose IV dually-
infected macaques indicates that the X4 virus is not intrinsically
better fit for replication if there is no transmission bottleneck.
Increased representation of the R5 virus in the mixed inoculum
favors its transmission by the mucosal route
Genetic bottlenecks present during IVAG transmission
results in a restriction of the quasispecies and may influence
the ability of the virus to establish infection within the host. To
determine whether we can bias towards R5 SHIVSF162P3 vaginal
transmission and favor its replication by increasing its relative
frequency in the mixed inocula, six RMwere exposed weekly to
100 TCID50 mix incoula containing 25 TCID50 of X4
SHIVSF33A and 75 TCID50 of R5 SHIVSF162P3, a three-fold
increase in R5 representation. Six of six exposed macaques
were shown to be systemically infected after 13 exposures, with
a probability of transmission of 0.167. Peak viremia varied ∼4
log among the infected animals. BG15 and CE75, the two
macaques with the highest peak viremia (>106 RNA copies/ml)
sustained viral load of >104 RNA copies/ml plasma, and
progressed to SAIDS at 47 and 42 wpi respectively (Fig. 5).Fig. 5. Viremia (A), CD4+ T cell counts (B) and genotype (C) of the replicating viru
SHIVSF162P3 and 25 TCID50 of X4 SHIVSF33A. For genotyping, the percentage of cConsistent with the precipitous drop in peripheral CD4+ T cells
seen in these two macaques, genotyping revealed the presence
of both viruses, but only the R5 virus was detected in BG34,
BH71, CB16 and CT25. Thus, it is indeed possible to increase
the risk of R5 virus transmission vaginally by increasing its
representation in the mixed inoculum. The increased probability
of transmission of the R5 SHIV in the 3:1 (0.167) compared to
1:1 (0.03) mixed inoculum is significant (p=0.034).
It is worthy of note that when X4 virus is transmitted with R5
virus under low-dose mixed vaginal challenge settings, the X4
virus has an advantage in outgrowing the R5 virus (BG15 and
CE75; and R024 in Fig. 4A). Collectively, these data suggest that
in the presence of transmission bottleneck, variants of HIV-1 are
transmitted in a frequency proportional to their representation in
the inoculum. However, in low-dose exposed macaques where
both viruses are transmitted simultaneously, X4 virus replication
predominates. Significantly, this X4 dominance is not seen after
IV low-dose mixed challenges (Fig. 4B) or, as previously
reported, in high-dose co-infected macaques (Harouse et al.,
2003). This then raises the possibility that there are properties of
the X4 inoculum that allow it to establish a systemic infection
more efficiently following low-dose vaginal transmission, but
which are not necessary or play a lesser role in intravenous
infections and high-dose vaginal challenges.
Discussion
In this study, we determine whether transmission and
infection outcome differ in RM exposed IVAG to repeated
small doses or to a single large inoculum dose, and whether
there are differences in susceptibility of X4 and R5 viruses to
the “inoculum effects”. Exposure to repeated low doses of
pathogenic R5 SHIVSF162P3 or X4 SHIVSF33A results in
infections that are blunted and are rapidly controlled. Surpris-
ingly, we find that transmission of the R5 virus is more
susceptible than X4 to the inoculum effect. The probability of
low-dose IVAG transmission is greater for the X4 SHIV than R5
SHIV, and in contrast to the observations previously made with
high-dose mixed inoculum, the X4 virus predominates in low-
dose IVAG dually-infected macaques. Thus, vaginal mucosal
transmission and infection with X4 SHIVSF33A can be achieved
quite efficiently at low doses. Microbicides and vaccinations in macaques exposed weekly to mixed inocula consisting of 75 TCID50 of R5
irculating X4 virus is shown. +Indicates progression to simian AIDS (SAIDS).
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both X4 and R5 viruses.
Contrary to what is observed with single high-dose IVAG
inoculations, a number of exposures are needed to establish
systemic infection with low-dose SHIV challenges. Furthermore,
significantly lower values of the geometric mean peak viremia
are seen in the low- compared to high-dose X4 or R5 SHIV
infected macaques (p<0.02) (Fig. 6). Considerable bottlenecks
are operational in vaginal transmission, resulting in fitness loss
and random transmission of variants (Greenier et al., 2001;
Muller, 1964; Neildez et al., 1998; Zhu et al., 1993), as well as
spontaneous resolution of infection (Wick and Self, 2000). In this
regard, the attenuated infection and the transmission of minor
viral variants seen in X4 and R5 low-dose infected macaques
(Figs. 2 and 3), and the presence of either X4 or R5 virus in a
majority of macaques exposed to multiple low doses of mixed
inocula (Figs. 4 and 5) are consistent with the fitness loss and
stochastic nature of IVAG infection, and which are accentuated
with the use of small inoculum dose.
The dose effect seen here for both X4 and R5 SHIV IVAG
infection differs from reports for the pathogenic SIVmac251
isolate and its molecular clone derivative SIVmac239. Although
a period of transient viremia precedes the onset of systemic
infection with low-dose SIVmac251 or SIVmac239 mucosal
exposures, once established, viral RNA levels in the low-dose
infected macaques were similar to that seen in classic systemic
infection that follows high-dose challenge (Ma et al., 2004;
McDermott et al., 2004; Neildez et al., 1998). Although
different routes of inoculation and challenge dose were
employed in the various studies, it is conceivable that optimally
adapted and highly virulent strains, especially very pathogenic
molecular clones, are less susceptible to a dose effect. Indeed,
SIVmac251 was derived through several passages in RM over a
period of 10 years following the inadvertent transmission of
SIVsm from sooty mangabeys to macaques (Mansfield et al.,
1995). In contrast, X4 SHIVSF33A was recovered from a
macaque infected with the molecular clone SHIVSF33 2 years
after infection (Luciw et al., 1999), and R5 SHIVSF162P3 wasFig. 6. Comparison of peak viremia in macaques infected with high and repeated
low dose R5 or X4 SHIVs. The bar indicates median value for the various
groups. Viral load data was transformed to logarithmic values for statistical
comparison. p values, two-tailed t-tests.generated through three successive, rapid serial passages of
clone SHIVSF162 in RM (Harouse et al., 2001), with a total
passage time in RM of ∼26 weeks. These SHIVs, in particular
the R5 SHIV, are likely to be less well adapted to RM compared
to SIV. The finding that R5 SHIVSF162P3 is more susceptible to
an inoculum effect than X4 SHIVSF33A is consistent with it
being less well adapted. When choosing an animal model to use
for testing intervention strategies, these differences in char-
acteristics of repetitive mucosal SIV and SHIV challenges
should be taken into consideration.
Intriguingly, we observe that the probability of transmission
with repeated low-dose X4 exposure is greater than with the R5
virus (p=0.048). The selective advantage of low-dose IVAG X4
SHIVSF33A transmission was also seen in the context of equal
mixed infection experiments, and contrary to what we
previously reported in high-dose dually-infected macaques
(Harouse et al., 2003), the X4 virus dominated in low-dose
dually-infected animals (Figs. 4A and 5). Our inocula are based
on tissue culture and not animal infectious dose of the two
viruses and it could be argued that due to in vitro titration
conditions, the R5 inoculum dose used was in fact lower.
However, we find similar transmission rates after repeated
vaginal exposures to 50 TCID50 or IV inoculations with 25
TCID50 of the two viruses. And, once infected, the geometric
mean or median peak viremia in macaques infected IVAG with
50 TCID50 of the R5 SHIVSF162P3 are not lower than those
infected with equal TCID50 of X4 SHIVSF33A (R5/low vs X4/
low, Fig. 6), which would have been expected if the infectious
dose of the R5 virus is indeed underestimated. Furthermore, the
selective advantage of low-dose X4 SHIV transmission and its
dominance is route dependent (Fig. 4), seen with IVAG and not
IV co-challenge, suggesting that the X4 inoculum is not more
infectious if there is no genetic bottleneck.
What then, could be the underlying basis for the selective
advantage of X4 SHIVSF33A transmission and efficiency in
establishing a generalized infection following low-dose intra-
vaginal challenges if the inoculum dose is indeed matched. It is
conceivable that differences in target cell availability or
susceptibility of X4 and R5 SHIVs to innate immunity in the
vaginal mucosa are playing a role. However, the finding that the
probability of low-dose transmission of the R5 virus can be
increased by tripling its representation in the inocula makes
these possibilities less plausible. Instead, we favor the inter-
pretation that because the X4 SHIVSF33A virus population has
been replicating and subjected to selection in the macaque host
for a longer time period than R5 SHIVSF162P3, it is better
adapted and is more heterogeneous in terms of genetic diversity
and complexity. These in turn, render the X4 virus less
susceptible to the genetic bottlenecks imposed by IVAG
inoculation, allowing for better establishment of a generalized
infection. This interpretation is supported by several observa-
tions. (i) The X4 inoculum is more complex, containing
approximately four times more RNA copies per tissue culture
infectious dose than R5. Since variants of HIV-1 are transmitted
in a frequency dependent manner (Frater et al., 2006) (Fig. 5),
more X4 variants are expected to be transmitted compared to R5
even when the infectious doses are matched. And, although the
214 L. Tsai et al. / Virology 362 (2007) 207–216vast majority of variants within the virus population appear to
be defective given the high RNA copy number to tissue culture
infectious dose ratios, these genomes can nevertheless con-
tribute to increase host cell tropism and virulence through
complementation and/or recombination (Charpentier et al.,
2006; Lori et al., 1992). (ii) As each round of replication
generates mutations, the X4 inoculum which contains four
times greater RNA copy numbers is expected to be more diverse
as well. While env and gag sequencing did not reveal significant
differences in the average genetic distance between major
variants within the X4 and R5 virus populations (Fig. 7),
heterogeneity among minor variants, or heterogeneity in other
regions of the genome that contribute to viral diversity, cannot
be excluded. The difference in passage history of the two
viruses, as well as a greater tendency for transmission of minor
variants in the X4 inoculum (Fig. 3) is also consistent with it
being more heterogeneous than the R5 SHIV. (iii) Since the
severity of the bottleneck effects is dependent on inoculum
dose, this would explain for our findings of X4 dominance
under low- (Fig. 4) but not high-dose vaginal co-infection as
reported previously (Harouse et al., 2003). Further studies are
needed to fully elucidate the underlying basis for efficient low-
dose vaginal transmission of X4 SHIVSF33A.
Efficient X4 SHIVSF33A transmission in RM vaginally
challenged with small inoculum dose, and even from inocula
containing both X4 and R5 SHIVs raises the question of why
natural sexual transmission of HIV-1 X4 viruses is relatively
rare in humans (Moore et al., 2004). We suggest that in
addition to or in spite of tropism, the predominance of HIV-1
R5 early in infection in humans is the consequence of greater
diversity and quantitative representation of R5 genomes in the
viral inocula. R5 viruses persist during all stages of infection
while X4 variants appear in about 50% of infected individuals
at end stage disease (Koot et al., 1993). The genome copy
number of R5 virus in inocula from individuals transmitting
during the early stages of their infection is therefore in vast
excess compared to those of the X4 virus. At late stage
infection and with the appearance of X4 variants, the R5 virus
may still have an advantage since its quasispecies is expected
to be more diverse, having been replicating in the transmittersFig. 7. Viral population diversity of X4 SHIVSF33A and R5 SHIVSF162P3 inocula. Ge
for viral RNA in the inocula are shown. Sequences from at least 20 clones each wfor longer periods of time. Furthermore, it is likely that
patients at end stage disease are less likely to participate
actively in sexual activities.
In summary, our study describes characteristics of repeated
low dose vaginal transmission and infection with viruses that
resemble HIV-1. Multiple low-dose exposure models that use
the number of challenges required to establish infection rather
than reduction in viral load as end points should aid in the
development and pre-clinical evaluation of vaccine and
microbicide strategies using experimental models that have a
high degree of variability in infection outcome but nevertheless,
may be more relevant to natural infection. Importantly, the
unexpected finding of efficient low dose X4 SHIVSF33A IVAG
transmission leads to the hypothesis of a link between greater
genetic heterogeneity of an inoculum and its enhanced vaginal
transmission capacity. We propose that this is among the
reasons for selective sexual transmission of CCR5-utilizing
HIV-1 in human.
Materials and methods
Virus and animal inoculations
Cell-free stocks of X4 SHIVSF33A and R5 SHIVSF162P3 were
propagated and titrated in a CEMX174.CCR5 cell line (5.25.
eGFP.Luc.M7) (Brandt et al., 2002). The in vitro titer of R5
SHIVSF162P3 was 5.13×10
3 TCID50 and 9×10
8 RNA copies/ml,
while that of X4 SHIVSF33Awas 1.58×10
3 TCID50 and 1.1×10
9
RNA copies/ml. For IVAG inoculations, 1–2 ml of virus, either
undiluted or diluted in media to produce an inoculum containing
50–100 TCID50 of X4, R5 or varying proportions of the two was
deposited atraumatically onto the cervicovaginal mucosa. The
animals were kept with their pelvis elevated for 20 min after
virus exposures. All exposures were carried out with female
Indian RM (Macaca mulatta) individually housed at the Tulane
National Primate Research Center (TNPRC) in compliance with
the Guide for the Care and Use of Laboratory Animals, and the
studies were reviewed and approved by the Institutional Animal
Care and Use Committee at TNPRC. Animals were not
experimentally cycled and were confirmed to be serologicallynetic distances between all possible pairs of Env and Gag nucleotide sequences
ere analysed and bars indicate median values.
215L. Tsai et al. / Virology 362 (2007) 207–216negative for simian type D retrovirus, SIV and simian T-cell
lymphotropic virus before use.A single high dose inoculationwas
performed whereas inoculation with low dose virus was repeated
weekly for a maximum of 13 exposures or until systemic SHIV
infection could be documented. Systemic infection is defined as at
least two consecutive plasma viral RNA (vRNA) positive time
points above the limit of detection (125 RNA copies/ml),
regardless of viral load. Whole blood was collected at weekly
intervals and plasma virus was quantified by an SIV-specific
branched DNA (bDNA) signal amplification assay (Bayer
Diagnostics, Emeryville, CA). T cell subsets (CD3+, CD4+,
and CD8+ T lymphocytes) were determined by Trucount flow
cytometry analysis (Becton Dickinson, San Jose, CA). Animals
with clinical signs of simian AIDS (SAIDS) or at the end of the
study were euthanized by intravenous administration of keta-
mine–HCl followed by an overdose of sodium pentobarbital. For
this study, any two of the following clinical signs [opportunistic
infections (MAI or CMV), >20% weight loss, muscle wasting,
diarrhea] coupled with virological and immunological indicators
and histological findings were used as criteria for defining simian
AIDS (SAIDS).
Virus genotype
The relative proportion of replicating X4 and R5 virus in the
plasma of dually-exposed macaques was determined by real-
time PCR that distinguishes the two viruses (Boadi et al., 2005).
Briefly, viral RNA was extracted from plasma, reversed
transcribed and the V1–V5 region of envelope gp120 amplified
with the conserved ED5/ED12 primers (Delwart et al., 1993).
Ten-fold dilutions of the first round PCR products were then
subjected to separate X4- and R5-specific real-time PCR
reactions. Standard curves were generated in parallel with
serial 10-fold dilutions of a known quantity of the X4 or R5
reference strain plasmid. Copy numbers of X4 SHVSF33A and
R5 SHIVSF162P3 sequences were calculated from the standard
curves and expressed as relative percentages.
Heteroduplex mobility assay (HMA)
A 648-bp fragment encompassing the V3–V5 region of
gp120 was amplified from cDNA using the ED5/ED12 and the
ED7/ED8 primers in a nested PCR reaction. A corresponding
fragment was also prepared from the reference HIV-1SF128A
plasmid DNA. An excess amount of the HIV-1SF128A amplified
fragment was then mixed with the PCR products to promote
heteroduplex formation as previously described (Delwart et al.,
1993). Samples were run on non-denaturing 5% polyacrylamide
gels and stained with ethidium. To avoid genetic variations
introduced in response to immune pressure, d14–d21 post-
infection plasma samples obtained before full seroconversion
were analyzed.
DNA sequencing and analysis
Nested PCR was used to amplify a 900-bp SIV gag
fragment from cDNA as described (Chen et al., 1996). The gagproduct, together with a 1200-bp V1–V5 Env PCR product
amplified using the ED5/ED12 primers were subjected to
TOPO TA cloning (Invitrogen, Carlsbad, CA), and the ligates
were used for transformation. Plasmid DNA of at least 20
clones from each transformation was purified using the
QIAprep Miniprep Kit (Qiagen, Valencia, CA), and sequencing
was performed by SeqWright (Fisher Scientific, Houston, TX).
Nucleotide sequences were aligned using the CLUSTALX 1.81
program, and further adjusted manually (Jeanmougin et al.,
1998). Pairwise genetic distances were calculated using
Kimura's 2-parameter model of molecular evolution (Kimura,
1980).
Statistics
Fisher's exact or unpaired tests were used to compare
characteristics of R5 and X4 SHIV infections, and logrank
Mantel–Cox test for the Kaplan–Meier analysis was performed
to determine the significance of the difference in probability of
transmission with repeated low dose R5 and X4 SHIV.
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